High Points and Hurdles: Immunotherapy Moves Forward

Anita T. Shaffer @Shaffer1
Published: Wednesday, Jun 27, 2012
When it comes to the immunotherapy field as a whole, Kirkman believes researchers remain excited about its possibilities, but that enthusiasm does not necessarily translate to raising capital.

“The investor world is a little fickle and waxes and wanes on the subject,” said Kirkman. “It took a very long time for anything to actually get approved, and we now have two approved immunotherapy products, Provenge for prostate cancer and Yervoy for melanoma, and that certainly has helped the field immensely.

“Over the next 12 months, we’re going to get a number of additional phase III immunotherapy trials coming to a conclusion,” noted Kirkman. “If one or more of those is successful, then it will pretty much answer the question that immunotherapy works. And I’m hoping that Stimuvax is one of those compounds.”


References

  1. Topalian SL, Brahmer JR, Hodi FS, et al. Anti-PD1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: clinical activity, safety, and a potential biomarker of response. J Clin Oncol. 2012;30(suppl; abstr CRA2509).
  2. Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy [commentary]. J Transl Med. 2011;9:214-228.
  3. Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer [editorial]. J Transl Med. 2012;10:1-4.
  4. Dendreon Corp Form 10-K (Annual Report). Dendreon website. http://investor.dendreon.com/sec.cfm. Published February 29, 2012. Accessed June 10, 2012.
  5. Nabhan C, Gomella LG, DeVries T, et al. An analysis to quantify the overall survival (OS) benefit of sipuleucel-T accounting for the crossover in the control arm of the IMPACT study. J Clin Oncol. 2012;30(suppl 5;abstr 144).
  6. Oncothyreon 2011 Annual Report. Oncothyreon website. http://ir.oncothyreon.com/annuals.cfm. Published March 9, 2012. Accessed June 11, 2012.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Publication Bottom Border
Border Publication
x